Transcriptional profiling of the rat frontal cortex following administration of the mGlu5 receptor antagonists MPEP and MTEP

European Journal of Pharmacology

Volumn 584, Issue 2-3, 2008, Pages 253-262

  Gass, Justin T ^a   Olive, M Foster ^a  

^a MUSC Center for Drug and Alcohol Programs   (United States)

Author keywords

Antagonist; Frontal cortex; Gene expression; Glutamate; Hierarchical cluster analysis; Microarray; Pathway analysis; Type 5 metabotropic glutamate receptor mGlu5

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; ADENOSINE TRIPHOSPHATE; HYDROLASE; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVITY; FRONTAL CORTEX; GENE EXPRESSION; GENETIC TRANSCRIPTION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT; UNINDEXED SEQUENCE; UPREGULATION;

ADENOSINE TRIPHOSPHATE; ANIMALS; CEREBRAL CORTEX; CLUSTER ANALYSIS; ENERGY METABOLISM; EXCITATORY AMINO ACID ANTAGONISTS; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HYDROLASES; INJECTIONS, INTRAPERITONEAL; MALE; MAP KINASE SIGNALING SYSTEM; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PYRIDINES; RATS; RATS, WISTAR; RECEPTORS, METABOTROPIC GLUTAMATE; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIAZOLES; TRANSCRIPTION, GENETIC;

EID: 41249087635     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.02.032     Document Type: Article

References (64)

1. 3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization. J. Pharmacol. Exp. Ther. 303 (2002) 1044-1051
2. 3H]-methoxy-5-(pyridin-2-ylethynyl)pyridine). Eur. J. Pharmacol. 473 (2003) 35-40
3. Backstrom P., Bachteler D., Koch S., Hyytia P., and Spanagel R. mGluR5 antagonist MPEP reduces ethanol-seeking and relapse behavior. Neuropsychopharmacology 29 (2004) 921-928
4. Brodkin J., Bradbury M., Busse C., Warren N., Bristow L.J., and Varney M.A. Reduced stress-induced hyperthermia in mGluR5 knockout mice. Eur. J. Neurosci. 16 (2002) 2241-2244
5. Brodkin J., Busse C., Sukhoff S.J., and Varney M.A. Anxiolytic-like activity of the mGluR5 antagonist MPEP: a comparison with diazepam and buspirone. Pharmacol. Biochem. Behav. 73 (2002) 359-366
6. Charney D.S. Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Psychiatr. Scand., Suppl. 417 (2003) 38-50
7. Chiamulera C., Epping-Jordan M.P., Zocchi A., Marcon C., Cottiny C., Tacconi S., Corsi M., Orzi F., and Conquet F. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat. Neurosci. 4 (2001) 873-874
8. Choe E.S., and Wang J.Q. Group I metabotropic glutamate receptor activation increases phosphorylation of cAMP response element-binding protein, Elk-1, and extracellular signal-regulated kinases in rat dorsal striatum. Mol. Brain Res. 94 (2001) 75-84
9. Choe E.S., and Wang J.Q. Group I metabotropic glutamate receptors control phosphorylation of CREB, Elk-1 and ERK via a CaMKII-dependent pathway in rat striatum. Neurosci. Lett. 313 (2001) 129-132
10. Conn P.J. Physiological roles and therapeutic potential of metabotropic glutamate receptors. Ann. N.Y. Acad. Sci. 1003 (2003) 12-21
11. Conn P.J., and Pin J.-P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 37 (1997) 205-237
12. Cosford N.D., Tehrani L., Roppe J., Schwieger E., Smith N.D., Anderson J., Bristow L., Brodkin J., Jiang X., McDonald I., Rao S., Washburn M., and Varney M.A. 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J. Med. Chem. 46 (2003) 204-206
13. Coutinho V., and Knopfel T. Metabotropic glutamate receptors: electrical and chemical signaling properties. Neuroscientist 8 (2002) 551-561
14. Cowen M.S., Djouma E., and Lawrence A.J. The metabotropic glutamate 5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl)-pyridine reduces ethanol self-administration in multiple strains of alcohol-preferring rats and regulates olfactory glutamatergic systems. J. Pharmacol. Exp. Ther. 315 (2005) 590-600
15. de Novellis V., Marabese I., Palazzo E., Rossi F., Berrino L., Rodella L., Bianchi R., Rossi F., and Maione S. Group I metabotropic glutamate receptors modulate glutamate and g-aminobutyric acid release in the periaqueductal grey of rats. Eur. J. Pharmacol. 462 (2003) 73-81
16. Dougherty D.D., and Rauch S.L. Brain correlates of antidepressant treatment outcome from neuroimaging studies in depression. Psychiatr. Clin. North Am. 30 (2007) 91-103
17. Gasparini F., Lingenhohl K., Stoehr N., Flor P.J., Heinrich M., Vranesic I., Biollaz M., Allgeier H., Heckendorn R., Urwyler S., Varney M.A., Johnson E.C., Hess S.D., Rao S.P., Sacaan A.I., Santori E.M., Velicelebi G., and Kuhn R. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38 (1999) 1493-1503
18. Gass J.T., and Olive M.F. Glutamatergic substrates of drug addiction and alcoholism. Biochem. Pharmacol. 75 (2008) 218-265
19. Gerber U., Gee C.E., and Benquet P. Metabotropic glutamate receptors: intracellular signaling pathways. Curr. Opin. Pharmacol. 7 (2007) 56-61
20. Hermans E., and Challiss R.A. Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: prototypic family C G-protein-coupled receptors. Biochem. J. 359 (2001) 465-484
21. Homayoun H., and Moghaddam B. Bursting of prefrontal cortex neurons in awake rats is regulated by metabotropic glutamate 5 (mGlu5) receptors: rate-dependent influence and interaction with NMDA receptors. Cereb. Cortex 16 (2006) 93-105
22. Hou L., and Klann E. Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression. J. Neurosci. 24 (2004) 6352-6361
23. Irizarry R.A., Bolstad B.M., Collin F., Cope L.M., Hobbs B., and Speed T.P. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31 (2003) e15
24. Irizarry R.A., Hobbs B., Collin F., Beazer-Barclay Y.D., Antonellis K.J., Scherf U., and Speed T.P. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4 (2003) 249-264
25. Jia Z., Lu Y., Henderson J., Taverna F., Romano C., Abramow-Newerly W., Wojtowicz J.M., and Roder J. Selective abolition of the NMDA component of long-term potentiation in mice lacking mGluR5. Learn. Mem. 5 (1998) 331-343
26. Kalivas P.W., Volkow N., and Seamans J. Unmanageable motivation in addiction: a pathology in prefrontal-accumbens glutamate transmission. Neuron 45 (2005) 647-650
27. Kellinghaus C., and Luders H.O. Frontal lobe epilepsy. Epileptic Disord. 6 (2004) 223-239
28. Kenny P.J., and Markou A. The ups and downs of addiction: role of metabotropic glutamate receptors. Trends Pharmacol. Sci. 25 (2004) 265-272
29. A signaling. Neuropharmacology 47 (2004) 342-350
30. Lea P.M., and Faden A.I. Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP. CNS Drug Rev. 12 (2006) 149-166
31. Li X., Need A.B., Baez M., and Witkin J.M. Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J. Pharmacol. Exp. Ther. 319 (2006) 254-259
32. Liu F., Zhang G., Hornby G., Vasylyev D., Bowlby M., Park K., Gilbert A., Marquis K., and Andree T.H. The effect of mGlu5 receptor positive allosteric modulators on signaling molecules in brain slices. Eur. J. Pharmacol. 536 (2006) 262-268
33. - ΔΔCT method. Methods 25 (2001) 402-408
34. Mao L., and Wang J.Q. Interactions between ionotropic and metabotropic glutamate receptors regulate cAMP response element-binding protein phosphorylation in cultured striatal neurons. Neuroscience 115 (2002) 395-402
35. Mao L., and Wang J.Q. Metabotropic glutamate receptor 5-regulated Elk-1 phosphorylation and immediate early gene expression in striatal neurons. J. Neurochem. 85 (2003) 1006-1017
36. Mao L., and Wang J.Q. Phosphorylation of cAMP response element-binding protein in cultured striatal neurons by metabotropic glutamate receptor subtype 5. J. Neurochem. 84 (2003) 233-243
37. Mills C.D., Xu G.Y., McAdoo D.J., and Hulsebosch C.E. Involvement of metabotropic glutamate receptors in excitatory amino acid and GABA. release following spinal cord injury in rat. J. Neurochem. 79 (2001) 835-848
38. Nagel J., Greco S., Klein K.-U., Eilbacher B., Valastro B., Tober C., and Danysz W. Microdialysis reveals different brain PK of the selective mGluR5 negative modulators MTEP and MPEP. Program No. 711.19. 2007 Neuroscience Meeting Planner (2007), Society for Neuroscience, San Diego, CA Online
39. Nordquist R.E., Durkin S., Jaeschke G., and Spooren W. Stress-induced hyperthermia: effects of acute and repeated dosing of MPEP. Eur. J. Pharmacol. 568 (2007) 199-202
40. Olive M.F. mGlu5 receptors: neuroanatomy, pharmacology, and role in drug addiction. Curr. Psychiatry Rev. 1 (2005) 197-214
41. Owen A.M. Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry. Neuroscientist 10 (2004) 525-537
42. Pacheco R., Ciruela F., Casado V., Mallol J., Gallart T., Lluis C., and Franco R. Group I metabotropic glutamate receptors mediate a dual role of glutamate in T cell activation. J. Biol. Chem. 279 (2004) 33352-33358
43. Palucha A., and Pilc A. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol. Ther. 115 (2007) 116-147
44. Peavy R.D., and Conn P.J. Phosphorylation of mitogen-activated protein kinase in cultured rat cortical glia by stimulation of metabotropic glutamate receptors. J. Neurochem. 71 (1998) 603-612
45. Peavy R.D., Chang M.S., Sanders-Bush E., and Conn P.J. Metabotropic glutamate receptor 5-induced phosphorylation of extracellular signal-regulated kinase in astrocytes depends on transactivation of the epidermal growth factor receptor. J. Neurosci. 21 (2001) 9619-9628
46. Pietraszek M., Sukhanov I., Maciejak P., Szyndler J., Gravius A., Wislowska A., Plaznik A., Bespalov A.Y., and Danysz W. Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. Eur. J. Pharmacol. 514 (2005) 25-34
47. Pilc A., Klodzinska A., Branski P., Nowak G., Palucha A., Szewczyk B., Tatarczynska E., Chojnacka-Wojcik E., and Wieronska J.M. Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology 43 (2002) 181-187
48. Romano C., Sesma M.A., McDonald C.T., O'Malley K., van den Pol A.N., and Olney J.W. Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J. Comp. Neurol. 355 (1995) 455-469
49. Schoenbaum G., Roesch M.R., and Stalnaker T.A. Orbitofrontal cortex, decision-making and drug addiction. Trends Neurosci. 29 (2006) 116-124
50. Shigemoto R., and Mizuno N. Metabotropic glutamate receptors - immunocytochemical and in situ hybridization analysis. In: Ottersen O.P., and Storm-Mathisen J. (Eds). Handbook of Chemical Neuroanatomy: Metabotropic Glutamate Receptors: Immunocytochemical and In Situ Hybridization Analyses vol. 18 (2000), Elsevier, London 63-98
51. Shigemoto R., Nomura S., Ohishi H., Sugihara H., Nakanishi S., and Mizuno N. Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci. Lett. 163 (1993) 53-57
52. Shigeri Y., Seal R.P., and Shimamoto K. Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. Brain Res. Rev. 45 (2004) 250-265
53. Simonyi A., Schachtman T.R., and Christoffersen G.R. The role of metabotropic glutamate receptor 5 in learning and memory processes. Drug News Perspect. 18 (2005) 353-361
54. Slassi A., Isaac M., Edwards L., Minidis A., Wensbo D., Mattsson J., Nilsson K., Raboisson P., McLeod D., Stormann T.M., Hammerland L.G., and Johnson E. Recent advances in non-competitive mGlu5 receptor antagonists and their potential therapeutic applications. Curr. Top. Med. Chem. 5 (2005) 897-911
55. Spooren W., and Gasparini F. mGlu5 receptor antagonists: a novel class of anxiolytics?. Drug News Perspect. 17 (2004) 251-257
56. Spooren W.P., Vassout A., Neijt H.C., Kuhn R., Gasparini F., Roux S., Porsolt R.D., and Gentsch C. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J. Pharmacol. Exp. Ther. 295 (2000) 1267-1275
57. Swanson C.J., Bures M., Johnson M.P., Linden A.M., Monn J.A., and Schoepp D.D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat. Rev. Drug Discov. 4 (2005) 131-144
58. Tatarczynska E., Klodzinska A., Chojnacka-Wojcik E., Palucha A., Gasparini F., Kuhn R., and Pilc A. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br. J. Pharmacol. 132 (2001) 1423-1430
59. Tessari M., Pilla M., Andreoli M., Hutcheson D.M., and Heidbreder C.A. Antagonism at metabotropic glutamate 5 receptors inhibits nicotine- and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking. Eur. J. Pharmacol. 499 (2004) 121-133
60. Thomas L.S., Jane D.E., Gasparini F., and Croucher M.J. Glutamate release inhibiting properties of the novel mGlu5 receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP): complementary in vitro and in vivo evidence. Neuropharmacology 41 (2001) 523-527
61. Tian L., Greenberg S.A., Kong S.W., Altschuler J., Kohane I.S., and Park P.J. Discovering statistically significant pathways in expression profiling studies. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 13544-13549
62. Varty G.B., Grilli M., Forlani A., Fredduzzi S., Grzelak M.E., Guthrie D.H., Hodgson R.A., Lu S.X., Nicolussi E., Pond A.J., Parker E.M., Hunter J.C., Higgins G.A., Reggiani A., and Bertorelli R. The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles. Psychopharmacology 179 (2005) 207-217
63. Witkin J.M., Marek G.J., Johnson B.G., and Schoepp D.D. Metabotropic glutamate receptors in the control of mood disorders. CNS Neurol. Disord. Drug Targets 6 (2007) 87-100
64. Yang L., Mao L., Chen H., Catavsan M., Kozinn J., Arora A., Liu X., and Wang J.Q. A signaling mechanism from Gαq-protein-coupled metabotropic glutamate receptors to gene expression: role of the c-Jun N-terminal kinase pathway. J. Neurosci. 26 (2006) 971-980